Science to medicine®

LATEST NEWS

SEP
2

Regeneron Discovery on Cause of Rare Genetic Bone Disease Detailed in Science Translational Medicine Publication
More »

SEP
1

Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
More »

AUG
19

Regeneron is Named #4 Most Innovative Company in the World by Forbes
More »

OUR PIPELINE

Striving for new therapies that improve patients' lives


We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases, and allergic conditions.

  • OUR PEOPLE

    "Discovering and developing drugs to help patients takes years of hard work. There are no shortcuts in this business, but we always believed that we could succeed."


    Leonard Schleifer, MD, PhD, President and CEO

  • OUR PEOPLE

    "Regeneron is a place where new ideas are welcome. The environment fosters growth and progress that allows us to produce a product that meets the highest quality standards."


    Shazad Suchit, Quality Control Analyst III

  • OUR PEOPLE

    "Everything that we’ve been doing for 25 years interconnects. We're building on the foundation of those early ideas and taking them to the next level."


    George Yancopoulos, MD, PhD, Founding Scientist, President, Regeneron Laboratories and Chief Scientific Officer

  • OUR PEOPLE

    "Our drug development programs are propelled by the desire to address unmet medical needs, and all our work is done with the utmost integrity."


    Sumathi Sivapalasingam, Director Clinical Sciences Translational Medicine

OUR PROMISE

Integrity is a core value at Regeneron and lies at the heart of everything we do.


Learn more about our Corporate Responsibility, Ethics and Compliance.

Close
Form content here please :)